After a long and bumpy path to approval, the U.S. FDA has finally given the green light to Cyclopharm Ltd.'s Technegas combination product a day after the Sept. 29 PDUFA date. Technegas is a nuclear ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Cyclopharm Limited’s Technegas ...
Cyclopharm Limited (AU:CYC) has released an update. Cyclopharm Limited has announced that its radiopharmaceutical product, Technegas, has been granted Pass-Through reimbursement status by the Centre ...
PERTH, Australia – Sydney-based Cyclopharm Ltd. raised AU$30 million (US$23.19 million) in a private placement that will enable the company to launch its Technegas combination product in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results